Artemether-Lumefantrine Supplier and Exporter to Uganda

Malaria is endemic across most of Uganda and is one of the leading causes of illness and death, particularly among children under five. Artemisinin-based combination therapies such as Artemether-Lumefantrine are the recommended first-line treatment for uncomplicated malaria in Uganda, procured across the public health system, private pharmacies, and substantial donor-supported programmes. Demand for quality-assured ACTs is large and continuous.

Pharmaceutical products imported into Uganda require registration with the National Drug Authority (NDA). We work with Ugandan importer and distributor partners to register Artemether-Lumefantrine for the Ugandan market, providing the CTD and ACTD dossiers the NDA requires, with regulatory assistance through the process. If you are an established Ugandan importer looking to add a WHO-GMP ACT to your portfolio, we would like to hear from you.

We manufacture Artemether-Lumefantrine in 20/120 mg, 40/240 mg, and 80/480 mg strengths, in both standard and dispersible tablets for paediatric dosing, important given the malaria burden among Ugandan children. Packaging and labelling can be configured to the Ugandan market.

Once registered, Artemether-Lumefantrine can be supplied for Ugandan government malaria procurement (including through National Medical Stores), donor and NGO health programmes, and private-market distribution, with competitive volume pricing, flexible packaging, and private labelling.

MOQ and pricing depend on strength, formulation, packaging, and volume. We handle export logistics and documentation for shipments to Uganda, routed through the port of Mombasa. Request a quote with your requirements for exact terms.